I will stay focused on the same mission: improve the outcomes of CAR T-cell therapy patients – Jordan Gauthier
I’m happy to share that I’m now Associate Professor at Fred Hutch and University of Washington.
I will stay focused on the same mission: improve the outcomes of CAR T-cell therapy patients. Why?
– prolonged remissions after CAR-T are seen in less than 40% of patients.
– we see severe toxicities in up to 60% of patients. Specifically, neurologic toxicities can linger and do not always respond to corticosteroids.
How to achieve this?
– we are exploring new ways to safely boost anti-tumor effects (eg, optimized CAR constructs, new targets, cytokine support)
– we are testing creative strategies to prevent toxicities while maintaining anti-tumor efficacy
– we are rigorously assessing statistical and ML models to better predict outcomes. It’s not enough to build “fancy” models; they must be tied to practical interventions and ruthlessly validated.
– we are tightening our collaborations with many of our talented lab-based scientists including amongst others: Evan Newell Anthony Rongvaux sylvain simon Aaron Ring
The journey will continue to take us from *benches to trenches*, but we will also make progress by reverse-translating observations made in the clinic.
We would be doomed without the support from hundreds of colleagues: PCCs, MAs, RNs, APPs, CRCs, regulatory associates, PMs, administrative assistants, laboratory technologists… and many more. Your help is very much appreciated.
Lastly, I would like to thank my wife Emily Gauthier for her unwavering support and for periodically reminding me to recalibrate my work-life balance! 😅
Exciting times ahead.
Onward,
Jordan
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023